GLPBio

Ranitidine

Catalog No.: GC20026Purity:>98.00%

ラニチジンは、IC50が3.3μMで胃分泌を抑制する強力で選択的かつ経口的に有効なヒスタミンH2受容体拮抗薬です。

製品は研究用途にのみ使用できます。人体には使用できません。患者への販売は行っておりません。


Ranitidine
Cas No.: 66357-35-5
10mM (in 1mL DMSO)In Stock
$35.00
1
1gIn Stock
$21.00
1
5gIn Stock
$42.00
1
25gIn Stock
$60.00
1
100gIn Stock
$195.00
1

引用文献 (Citations)

現在、この製品の引用文献はありません。以下はGlpBio製品を引用した代表的な文献です。
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

製品説明 (Description)

Ranitidine, an inhibitor of gastric acid secretion, competitively antagonizes histamine-induced increases in contraction frequency with a pA2 value of 7.2[1]. Ranitidine inhibits the activity of yeast sucrose enzyme in a non-competitive manner and causes structural changes, with an IC50 value of 2.2mM[2]. Ranitidine attenuates rotenone-induced apoptosis by inhibiting the phosphorylation of JNK and p38, as well as the activation of CASP, thereby preventing the cleavage of PARP and CASP3[3]. Ranitidine has been widely used to inhibit liver regeneration in rats after liver resection and to suppress the cell mitotic activity of liver cells[4].

In vitro, Ranitidine (100µM) pretreatment for 20 minutes significantly inhibited the death of rat cortical neuron cells induced by oxygen-glucose deprivation (OGD), and suppressed the activation of caspase 3 as well as the changes in the cytoskeleton[5]. Treatment with 0.1µM Ranitidine for 48 hours significantly inhibited the growth of Caco-2 cells and induced cell apoptosis[6].

In vivo, Ranitidine treatment via oral administration at a dose of 8mg/kg/day for 8 days significantly reduced the number of CD11b+ Ly6Chi cells in the spleen and bone marrow of BALB/c mice[7]. Oral administration of Ranitidine at a dose of 30mg/kg/day for 14 days significantly increased locomotor exploratory behavior and reduced anxiety-related behavior in a mouse model of gastrointestinal disease[8].

References:
[1] Daly M J, Humphray J M, Stables R. Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine[J]. British journal of pharmacology, 1981, 72(1): 49.
[2] Minai-Tehrani D, Ghaffari M, Sobhani-Damavandifar Z, et al. Ranitidine induces inhibition and structural changes in sucrase[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27(4): 553-557.
[3] Park H J, Kim H J, Park H K, et al. Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis[J]. Neurotoxicology, 2009, 30(6): 1114-1119.
[4] Kanashima R, Nagasue N, Sakato K. Ranitidine as an inhibitor of liver regeneration[J]. The American journal of surgery, 1985, 149(2): 223-227.
[5] Malagelada C, Xifró X, Badiola N, et al. Histamine H2-receptor antagonist ranitidine protects against neural death induced by oxygen-glucose deprivation[J]. Stroke, 2004, 35(10): 2396-2401.
[6] Rajendra S, Mulcahy H, Patchett S, et al. The effect of H2 antagonists on proliferation and apoptosis in human colorectal cancer cell lines[J]. Digestive diseases and sciences, 2004, 49(10): 1634-1640.
[7] Vila-Leahey A, Oldford S A, Marignani P A, et al. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice[J]. Oncoimmunology, 2016, 5(7): e1151591.
[8] Selvaraj D B, Vergil Andrews J F, Anusuyadevi M, et al. Ranitidine alleviates anxiety-like behaviors and improves the density of pyramidal neurons upon deactivation of microglia in the CA3 region of the hippocampus in a cysteamine HCl-induced mouse model of gastrointestinal disorder[J]. Brain Sciences, 2023, 13(2): 266.

実験プロトコル (Protocol)

Cell experiment [1]:

Cell lines

SH-SY5Y cells

Preparation Method

SH-SY5Y cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin at 37°C with 5% CO2 and 95% saturated atmospheric humidity. Cells were seeded into 96-well microplates at a density of 5×103 cells/ml for 24h. In the presence or absence of rotenone (10μM; 24h), cells were treated with different concentrations (0, 1, 5, 10, 50, and 100μM) of Ranitidine for 24 hours, and cell viability was analyzed.

Reaction Conditions

0, 1, 5, 10, 50, and 100μM; 24h

Applications

Ranitidine treatment significantly inhibited the cell death of SH-SY5Y cells induced by rotenone in a dose-dependent manner.
Animal experiment [2]:

Animal models

Female C57BL/6 mice

Preparation Method

Female C57BL/6 mice (6 weeks old; 20-22g) were grouped in individually ventilated cages (IVC) and maintained under specific pathogen-free (SPF) conditions in an environment-controlled room (12h light/12h dark cycle, 21±2°C, 55% relative humidity) and had access to sterilized tap water and standard chow ad libitum. 2×105 E0771 cells in 100μl of Matrigel were injected subcutaneously into the mammary fat pad near the fourth nipple. The mice were given drinking water containing an 8mg/kg dose of Ranitidine every day for a period of 21 days. The volume of the tumor was determined by caliper measurements every second day using the equation volume = length × width2/2.

Dosage form

8mg/kg/day; 21 days; p.o.

Applications

Ranitidine treatment significantly decreased tumor growth in mice with E0771 xenografts.

References:
[1] Park H J, Kim H J, Park H K, et al. Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis[J]. Neurotoxicology, 2009, 30(6): 1114-1119.
[2] Vila-Leahey A, Oldford S A, Marignani P A, et al. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice[J]. Oncoimmunology, 2016, 5(7): e1151591.

製品資料 (Product Documents)

Purity:>98.00%Appearance:A solid

化学的性質 (Chemical Properties)

CAS番号
66357-35-5
分子式
C13H22N4O3S
分子量
314.39
溶解性
DMSO : 63mg/mL
保存条件
-20°C
一般的な注意事項
製品の溶解性データに基づいて適切な溶媒を選択してください。調製後は、凍結融解の繰り返しを避けるため、ストック溶液を小分けしてください。
ストック溶液は、-80°Cで保存する場合は6か月以内、-20°Cで保存する場合は1か月以内に使用してください。
溶解性を高めるには、チューブを37°Cに温め、適切な時間超音波処理してください。
配送条件
評価用サンプルは保冷剤とともに発送します。その他の容量は室温で発送し、ご要望に応じて保冷剤を同梱します。

計算ツール (Calculators)モル濃度 / 希釈 / 分子量 / 単位変換 / in vivo製剤 / 溶解度

g/mol

Reviews

Review for Ranitidine

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%